Sumitomo Dainippon Pharma and BehaVR announce landmark deal for multiple virtual reality digital therapeutics

October 22, 2021

OSAKA , Japan and NASHVILLE, Tenn. Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan ; Representative Director, President and CEO: Hiroshi Nomura ; Securities Code: 4506, First Section of TSE) and BehaVR , Inc.,(Head Office: TN, U.S.) announce today that the companies have signed definitive agreements to develop and commercialize both prescription digital therapeutics and general wellness products for treatment of Social Anxiety Disorder (SAD), Generalized Anxiety Disorder (GAD), and Major Depressive Disorder (MDD) with the goal of bringing much needed tools to tackle the escalating global anxiety and depression crisis.
Continue Reading
Sumitomo Dainippon Pharma and BehaVR announce landmark deal …

Read the source article at PR Newswire
2021-10-18 16:30:00

Share This Story!